Indicated for: type 2 diabetes mellitus
Route of administration: oral
Substance: rosiglitazone + metformin (thiazolidinedione antidiabetic + biguanide antidiabetic)
ATC: A10BD03 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Combinations of oral blood glucose lowering drugs)
Dose adjustment may be needed in kidney disease.
Periodic laboratory tests may be required during treatment.
Use during pregnancy only on medical advice.
Rosiglitazone+metformin is a combination medication used in the treatment of type 2 diabetes mellitus. Rosiglitazone belongs to the thiazolidinedione class and works by increasing insulin sensitivity in muscle, fat, and liver cells. Metformin, a biguanide, reduces hepatic glucose production and improves glucose utilization by tissues.
This combination is taken orally, usually twice daily, and is indicated for patients who fail to control their blood sugar levels through diet, exercise, or monotherapy. It is effective in reducing glycated hemoglobin (HbA1c) levels and preventing diabetes-related complications.
Common side effects include nausea, diarrhea, weight gain, and fluid retention. In rare cases, severe adverse reactions such as heart failure or lactic acidosis may occur. Regular monitoring of renal function and blood glucose levels is essential.
Rosiglitazone+metformin is a valuable therapeutic option for patients with type 2 diabetes, helping to achieve better glycemic control and reduce the risk of long-term complications.